Schwab Charles Investment Management Inc. maintained its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,036 shares of the specialty pharmaceutical company’s stock at the close of the first quarter. Schwab Charles Investment Management Inc. owned about 0.15% of Collegium Pharmaceutical worth $454,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. American International Group Inc. increased its holdings in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the period. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares during the last quarter. Macquarie Group Ltd. purchased a new position in Collegium Pharmaceutical in the fourth quarter worth $127,000. UBS Group AG grew its holdings in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Collegium Pharmaceutical in the first quarter worth $238,000. 83.13% of the stock is currently owned by institutional investors and hedge funds.
COLL has been the topic of several analyst reports. Piper Jaffray Companies set a $14.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, July 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, May 31st. ValuEngine raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Finally, HC Wainwright began coverage on shares of Collegium Pharmaceutical in a research note on Monday. They set a “buy” rating and a $21.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Collegium Pharmaceutical presently has an average rating of “Hold” and an average target price of $20.67.
TRADEMARK VIOLATION WARNING: This news story was posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/markets/schwab-charles-investment-management-inc-has-454000-holdings-in-collegium-pharmaceutical-inc-coll/1604225.html.
Collegium Pharmaceutical, Inc. (NASDAQ COLL) traded down 1.22% on Friday, reaching $10.49. 170,318 shares of the company were exchanged. The stock’s market capitalization is $310.15 million. The stock has a 50-day moving average price of $10.62 and a 200 day moving average price of $12.51. Collegium Pharmaceutical, Inc. has a 52 week low of $10.15 and a 52 week high of $20.55.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Analysts forecast that Collegium Pharmaceutical, Inc. will post ($3.00) earnings per share for the current year.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with our FREE daily email newsletter.